Search

everythinglearnresearchcommunity

for

Search:↓

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Testosterone affects blood pressure control and inflammation in male rats with endotoxic shock, and blocking certain hormones may help treat it.

α-MSH increases melanin production in moulting hair follicles, while AVT inhibits it.

The document concluded that FDA-approved treatments like minoxidil and finasteride are effective for hair loss, while the effectiveness of natural remedies and other non-approved treatments is not well-supported by evidence.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Cosmos caudatus extract is as effective as finasteride for treating benign prostatic hyperplasia without its side effects.

Hidradenitis suppurativa is a skin disease caused by the breakdown of the skin's natural immune barriers, especially around hair follicles.

Oral difelikefalin significantly reduces itch in notalgia paresthetica.

New compounds with carborane showed anti-androgen effects similar to flutamide.

Lower growth factors linked to balding in androgenetic alopecia.

Blocking a specific receptor slows down hair loss in mice.

Male hormones and their receptors play a key role in hair loss and skin health, with potential new treatments being explored.

Prolactin affects hair growth cycles and can cause early hair follicle regression.

Certain mice without specific receptors or mast cells don't lose hair from stress.

Overexpressing the mineralocorticoid receptor in mouse skin causes skin thinning, early skin barrier development, eye issues, and hair loss.

Brain-Derived Neurotrophic Factor (BDNF) slows down hair growth and promotes hair follicle regression.

A specific genetic mutation may increase male pattern baldness risk, especially in Europeans.

LPA3 is crucial for embryo implantation and links LPA to prostaglandin signaling.

No link found between specific genes and female pattern hair loss.

We need better ways to test and understand SARMs to make safer and more effective treatments.

A protein called ectodysplasin-A2 increases a hair growth inhibitor in balding cells, which could be a target for hair loss treatment.

Glucocorticoids and sex hormones affect skin health, with potential for targeted treatments to minimize side effects and treat skin conditions.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Genetic variation in the androgen receptor gene mainly causes early-onset hair loss, with maternal inheritance playing a key role.

Oestrogen and thyrotropin-releasing hormone affect prolactin and its receptor in human skin and hair, suggesting new treatment options for related conditions.

Removing part of the vitamin D receptor stops vitamin D from working properly.

Eph receptors and ephrins may be promising targets for treating diseases, but more understanding is needed for effective and safe therapies.

The mutated hairless gene causes hair loss by acting as a new type of corepressor affecting thyroid hormone receptors.

The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.

Hair follicles produce and respond to melatonin, affecting hair growth and sensitivity to estrogen.